<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="hed28143" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Head Neck</journal-id><journal-id journal-id-type="iso-abbrev">Head Neck</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">HED</journal-id><journal-title-group><journal-title>Head &amp; Neck</journal-title></journal-title-group><issn pub-type="ppub">1043-3074</issn><issn pub-type="epub">1097-0347</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12248274</article-id><article-id pub-id-type="pmcid-ver">PMC12248274.1</article-id><article-id pub-id-type="pmcaid">12248274</article-id><article-id pub-id-type="pmcaiid">12248274</article-id><article-id pub-id-type="pmid">40145145</article-id><article-id pub-id-type="doi">10.1002/hed.28143</article-id><article-id pub-id-type="publisher-id">HED28143</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of <styled-content style="fixed-case" toggle="no">HPV</styled-content>/p16 Status</article-title></title-group><contrib-group><contrib id="hed28143-cr-0001" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="MH">Meng&#8208;hua</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0002" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xing</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0003" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="FJ">Feng&#8208;jiao</given-names></name><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="hed28143-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="hed28143-cr-0004" contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="XL">Xian&#8208;lu</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0005" contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="SD">Shi&#8208;da</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0006" contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="QH">Qiao&#8208;hong</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0007" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="XY">Xi&#8208;yuan</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0008" contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="J">Jian</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0009" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Ying</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0010" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="ST">Shi&#8208;ting</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hed28143-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="SW">Shu&#8208;wei</given-names></name><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>chenshuw@sysucc.org.cn</email></address></contrib><contrib id="hed28143-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Song</surname><given-names initials="M">Ming</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7495-5895</contrib-id><xref rid="hed28143-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hed28143-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hed28143-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>songming@sysucc.org.cn</email></address></contrib></contrib-group><aff id="hed28143-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Head and Neck Surgery</named-content>
<institution>Sun Yat&#8208;Sen University Cancer Center</institution>
<city>Guangzhou</city>
<country country="CN">China</country>
</aff><aff id="hed28143-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>State Key Laboratory of Oncology in South China</institution>
<city>Guangzhou</city>
<country country="CN">China</country>
</aff><aff id="hed28143-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Guangdong Provincial Clinical Research Center for Cancer</institution>
<city>Guangzhou</city>
<country country="CN">China</country>
</aff><aff id="hed28143-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Operation Theater Services</named-content>
<institution>Sun Yat&#8208;Sen University Cancer Center</institution>
<city>Guangzhou</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Shu&#8208;wei Chen (<email>chenshuw@sysucc.org.cn</email>)<break/>
Ming Song (<email>songming@sysucc.org.cn</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2025</year></pub-date><volume>47</volume><issue seq="180">8</issue><issue-id pub-id-type="pmc-issue-id">492698</issue-id><issue-id pub-id-type="doi">10.1002/hed.v47.8</issue-id><fpage>2248</fpage><lpage>2259</lpage><history><date date-type="rev-recd"><day>17</day><month>1</month><year>2025</year></date><date date-type="received"><day>09</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-12 10:25:32.810"><day>12</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Head &amp; Neck</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="HED-47-2248.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:HED-47-2248.pdf"/><abstract><title>ABSTRACT</title><sec id="hed28143-sec-0001"><title>Background</title><p>Squamous cell carcinoma of the soft palate (SCCSP) represents a rare subtype of oropharyngeal cancer. This study aims to evaluate the treatment outcomes of SCCSP and to assess the prognostic significance of HPV status.</p></sec><sec id="hed28143-sec-0002"><title>Methods</title><p>Patients diagnosed with SCCSP between January 1981 and December 2021 were collected. Survival outcomes were compared.</p></sec><sec id="hed28143-sec-0003"><title>
<mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Results</mml:mtext></mml:mrow></mml:mrow></mml:math>
</title><p>In univariate analysis, primary surgery resulted in superior progression&#8208;free survival (PFS), overall survival (OS), and disease&#8208;specific survival (DSS) compared with definitive radiotherapy (<italic toggle="no">p</italic>&#8201;&lt;&#8201;0.05). Furthermore, multivariate analysis revealed that primary surgery independently correlated with superior PFS (HR&#8201;=&#8201;0.37, <italic toggle="no">p</italic>&#8201;=&#8201;0.002), OS (HR&#8201;=&#8201;0.55, <italic toggle="no">p</italic>&#8201;=&#8201;0.012), and DSS (HR&#8201;=&#8201;0.45, <italic toggle="no">p</italic>&#8201;=&#8201;0.020) in early&#8208;stage SCCSPs. Additionally, no significant prognostic differences were observed between HPV/p16 positive and HPV/p16 negative SCCSPs (<italic toggle="no">p</italic>&#8201;&gt;&#8201;0.05).</p></sec><sec id="hed28143-sec-0004"><title>
<mml:math id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Conclusion</mml:mtext></mml:mrow></mml:mrow></mml:math>
</title><p>Surgery yields superior oncological outcomes for early&#8208;stage SCCSP patients. HPV status does not demonstrate prognostic significance in SCCSP.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="hed28143-kwd-0001">HPV</kwd><kwd id="hed28143-kwd-0002">oropharyngeal cancer</kwd><kwd id="hed28143-kwd-0003">prognosis</kwd><kwd id="hed28143-kwd-0004">radiotherapy</kwd><kwd id="hed28143-kwd-0005">surgery</kwd><kwd id="hed28143-kwd-0006">treatment</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="12"/><word-count count="6100"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.9 mode:remove_FC converted:11.07.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="hed28143-cit-1001"><string-name name-style="western"><given-names>M.&#8208;h.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>F.&#8208;j.</given-names><surname>Li</surname></string-name>, et al., &#8220;<article-title>Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of <styled-content style="fixed-case" toggle="no">HPV</styled-content>/p16 Status</article-title>,&#8221; <source>Head &amp; Neck</source><volume>47</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>2248</fpage>&#8211;<lpage>2259</lpage>, <pub-id pub-id-type="doi">10.1002/hed.28143</pub-id>.<pub-id pub-id-type="pmid">40145145</pub-id><pub-id pub-id-type="pmcid">PMC12248274</pub-id></mixed-citation>
</p><fn-group id="hed28143-ntgp-0001"><fn fn-type="equal" id="hed28143-note-0001"><p>Meng&#8208;hua Li, Xing Zhang, and Feng&#8208;jiao Li contributed equally to this work.</p></fn></fn-group></notes></front><body id="hed28143-body-0001"><sec id="hed28143-sec-0005"><label>1</label><title>Introduction</title><p>The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen dramatically on a global scale, largely attributed to the increasing prevalence of human papillomavirus (HPV) within the population [<xref rid="hed28143-bib-0001" ref-type="bibr">1</xref>]. The oropharynx is comprised of four primary subsites: the tonsils, the base of tongue, the soft palate, and the posterior pharyngeal walls. Squamous cell carcinoma of the soft palate (SCCSP) is a relatively rare entity, accounting for approximately 10% of all OPSCCs [<xref rid="hed28143-bib-0002" ref-type="bibr">2</xref>]. In comparison to tonsillar&#8208;related OPSCCs (squamous cell carcinomas of the tonsils and the base of tongue), SCCSP is linked to a poorer prognosis, with a reported 5&#8208;year survival rate of only about 40% [<xref rid="hed28143-bib-0003" ref-type="bibr">3</xref>, <xref rid="hed28143-bib-0004" ref-type="bibr">4</xref>].</p><p>The soft palate is composed of a stratified squamous epithelium that lacks a keratinized layer, similar to the epithelium found in the oral cavity. In contrast to the tonsillar&#8208;related areas in the oropharynx, lymphoid tissue is not abundantly present in the soft palate [<xref rid="hed28143-bib-0005" ref-type="bibr">5</xref>]. Previous research has indicated that HPV&#8208;positive OPSCC demonstrates a high responsiveness to treatment and is associated with a favorable prognosis. However, the occurrence of HPV&#8208;positive disease in the soft palate is relatively infrequent [<xref rid="hed28143-bib-0006" ref-type="bibr">6</xref>]. Furthermore, the prognostic implications of HPV status in SCCSP remain ambiguous due to its rarity. Given that SCCSPs are typically located superficially and can be readily visualized during examination, they can often be diagnosed at an early stage. The management of SCCSP is still a subject of controversy, with ongoing debates regarding treatment modalities, including surgery and radiotherapy [<xref rid="hed28143-bib-0007" ref-type="bibr">7</xref>]. Additionally, literature specifically addressing SCCSP is limited, and there is a scarcity of studies featuring large sample sizes and long&#8208;term outcome data.</p><p>In this study, we aim to evaluate the treatment outcomes of patients with SCCSP and to assess the influence of HPV status on prognosis within a large tertiary cancer center located in South China.</p></sec><sec id="hed28143-sec-0006"><label>2</label><title>Patients and Methods</title><sec id="hed28143-sec-0007"><label>2.1</label><title>Patient Identification and Data Collection</title><p>We retrospectively included consecutive patients diagnosed with SCCSP between January 1981 and December 2021 at the Sun Yat&#8208;sen University Cancer Center, a tertiary referral center located in South China. Clinical, pathological, and demographic information was extracted from the medical records of eligible patients. The inclusion criteria were as follows: (i) histologically confirmed squamous cell carcinoma located in the soft palate or uvula; (ii) a minimum of 2&#8201;years of clinical follow&#8208;up for patients who did not experience tumor progression or who were alive at the last follow&#8208;up. Patients with distant metastatic disease or other uncontrolled malignancies at the time of initial presentation were excluded from the study. This study was approved by our hospital's Institutional Review Board, and the ethics committee review specifically waived the need for informed consent.</p><p>HPV/p16 positivity was determined through the detection of high&#8208;risk HPV types utilizing the real&#8208;time polymerase chain reaction (RT&#8208;PCR) method or by positive immunohistochemistry for p16, characterized by diffuse and strong cytoplasmic and nuclear staining in more than 70% of tumor cells [<xref rid="hed28143-bib-0008" ref-type="bibr">8</xref>]. In this study, tumor staging was conducted in accordance with the seventh edition of the American Joint Committee on Cancer (AJCC) staging guidelines for oropharyngeal cancers. The eighth edition of the AJCC staging guidelines was not applied due to the unknown HPV/p16 status in a significant proportion of the patient cohort.</p></sec><sec id="hed28143-sec-0008"><label>2.2</label><title>Treatment Groups</title><p>Patients were evaluated by our multidisciplinary head and neck cancer board before the commencement of treatment. The initial treatment approach was categorized into two groups: the primary surgery group and the definitive radiotherapy group.</p><p>The primary surgery cohort comprised patients who underwent surgery with curative intent. Unilateral or bilateral therapeutic neck dissection was conducted for patients with clinically suspected lymph node metastasis, while prophylactic lymph node dissection was not actively performed for patients with cN0 tumors.</p><p>The definitive radiotherapy cohort comprised patients who underwent radiotherapy, either alone or in conjunction with concurrent therapy, which may or may not have included induction chemotherapy. The concurrent therapy regimen encompassed platinum&#8208;based therapies and Nimotuzumab, or was combined with oral fluorouracil (capecitabine). Induction chemotherapy involved platinum&#8208;based therapies in combination with paclitaxel&#8208;based therapies, or was administered alongside either 5&#8208;fluorouracil or oral fluorouracil (capecitabine).</p></sec><sec id="hed28143-sec-0009"><label>2.3</label><title>Outcomes and Statistical Analysis</title><p>Differences in patient characteristics concerning treatment regimens and HPV/p16 status were analyzed using the Student's <italic toggle="yes">t</italic>&#8208;test, Fisher's exact test, Mann&#8211;Whitney <italic toggle="yes">U</italic> test, and chi&#8208;squared test. The survival endpoints included progression&#8208;free survival (PFS), overall survival (OS), and disease&#8208;specific survival (DSS). PFS was defined as the interval from the date of initial treatment to the date of tumor progression, which encompassed local recurrence, lymph node metastasis, distant metastasis, or death, with surviving patients without evidence of disease being censored at the last follow&#8208;up. OS was calculated from the date of diagnosis to the date of death from any cause, with surviving patients censored at the last follow&#8208;up. DSS was calculated from the date of diagnosis to the date of death specifically from SCCSP, with patients who did not experience SCCSP&#8208;related death being censored at the date of the last follow&#8208;up or at the time of non&#8208;SCCSP&#8208;related death. Survival time was estimated using the Kaplan&#8211;Meier method and compared using the log&#8208;rank test for significance. The Cox proportional regression model was used for multivariate analysis. All tests were two&#8208;sided. A <italic toggle="yes">p</italic>&#8208;value of less than 0.05 was considered statistically significant. All data were analyzed using SPSS 26 software (SPSS, Chicago, IL).</p></sec></sec><sec sec-type="results" id="hed28143-sec-0010"><label>3</label><title>Results</title><sec id="hed28143-sec-0011"><label>3.1</label><title>Characteristics of Patients</title><p>A total of 256 consecutive patients were enrolled in this study. All patients were ethnic Chinese. The mean age at diagnosis was 57.63&#8201;years, with a notable male predominance observed (91.4%). A majority of the patients (68.8%) were smokers, and approximately half of these individuals (49.2%) were drinkers. Twenty&#8208;two patients had a prior history of cancer, with 14 cases located in the head and neck region and 8 cases in other anatomical sites. The baseline characteristics of the study population are summarized in Table&#160;<xref rid="hed28143-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="hed28143-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Patient and tumor characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Primary surgery, <italic toggle="yes">n</italic>&#8201;=&#8201;99 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Definitive RT, <italic toggle="yes">n</italic>&#8201;=&#8201;148 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HPV/p16+, <italic toggle="yes">n</italic>&#8201;=&#8201;25 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HPV/p16&#8722;, <italic toggle="yes">n</italic>&#8201;=&#8201;62 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="center" valign="top" rowspan="1" colspan="1">57.63 (9.44)</td><td align="center" valign="top" rowspan="1" colspan="1">57.32 (8.67)</td><td align="center" valign="top" rowspan="1" colspan="1">57.57 (9.87)</td><td align="center" valign="top" rowspan="1" colspan="1">0.156</td><td align="center" valign="top" rowspan="1" colspan="1">55.20 (9.03)</td><td align="center" valign="top" rowspan="1" colspan="1">56.87 (9.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.439</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.218</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">234 (91.4)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (87.9)</td><td align="center" valign="top" rowspan="1" colspan="1">138 (93.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">22 (88.0)</td><td align="center" valign="top" rowspan="1" colspan="1">59 (95.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">22 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (12.1)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (6.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoker</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">80 (31.2)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (39.4)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (25.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">176 (68.8)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (60.6)</td><td align="center" valign="top" rowspan="1" colspan="1">110 (74.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">18 (72.0)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (74.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drinker</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.296</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">130 (50.8)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (56.6)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (46.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (48.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">126 (49.2)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (43.4)</td><td align="center" valign="top" rowspan="1" colspan="1">79 (53.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">18 (72.0)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (51.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous cancer</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.034</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">234 (91.4)</td><td align="center" valign="top" rowspan="1" colspan="1">85 (85.9)</td><td align="center" valign="top" rowspan="1" colspan="1">141 (95.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">23 (92.0)</td><td align="center" valign="top" rowspan="1" colspan="1">57 (91.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">22 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV/p16 status</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.004</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">62 (71.3)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (84.6)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (51.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">25 (28.7)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (15.4)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (48.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">169</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">115</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RN involved</td><td align="center" valign="top" rowspan="1" colspan="1">24 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">20 (13.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.272</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cT stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.796</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1</td><td align="center" valign="top" rowspan="1" colspan="1">81 (31.6)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (35.4)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (30.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (30.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T2</td><td align="center" valign="top" rowspan="1" colspan="1">113 (44.1)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (56.6)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (37.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11 (44.0)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (46.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T3</td><td align="center" valign="top" rowspan="1" colspan="1">29 (11.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (14.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (12.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T4</td><td align="center" valign="top" rowspan="1" colspan="1">33 (12.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (16.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cN stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.652</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N0</td><td align="center" valign="top" rowspan="1" colspan="1">140 (54.7)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (60.6)</td><td align="center" valign="top" rowspan="1" colspan="1">79 (53.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">15 (60.0)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (54.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N1</td><td align="center" valign="top" rowspan="1" colspan="1">31 (13.3)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (11.1)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (15.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (12.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N2</td><td align="center" valign="top" rowspan="1" colspan="1">74 (28.9)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (25.3)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (28.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (32.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N3</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall c&#8208;stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.381</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">60 (23.4)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (27.3)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (22.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (24.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">II</td><td align="center" valign="top" rowspan="1" colspan="1">62 (24.2)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (29.3)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (21.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (22.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">III</td><td align="center" valign="top" rowspan="1" colspan="1">42 (16.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (18.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (19.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IVa</td><td align="center" valign="top" rowspan="1" colspan="1">79 (30.9)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (24.2)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (32.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (33.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IVb</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary surgery</td><td align="center" valign="top" rowspan="1" colspan="1">99 (38.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (71.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Definitive RT</td><td align="center" valign="top" rowspan="1" colspan="1">148 (57.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">16 (64.0)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (27.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">RT/CRT</td><td align="center" valign="top" rowspan="1" colspan="1">118</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ICT&#8201;+&#8201;RT/CRT</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Palliative</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="hed28143-ntgp-0002"><fn id="hed28143-note-0002"><p>
<italic toggle="yes">Note</italic>: Continuous values are presented as numbers or mean&#8201;&#177;&#8201;SD.</p></fn><fn id="hed28143-note-0003"><p>Abbreviations: CRT, chemoradiotherapy; c&#8208;stage, clinical stage; ICT, induction chemotherapy; RN, Retropharyngeal nodes; RT, radiotherapy.</p></fn></table-wrap-foot></table-wrap><p>The majority of patients initially presented with early T&#8208;stage (T1&#8208;2; <italic toggle="yes">n</italic>&#8201;=&#8201;194, 75.7%) and early N&#8208;stage diseases (N0&#8208;1; <italic toggle="yes">n</italic>&#8201;=&#8201;171, 68.0%). Additionally, 141 patients (55.1%) were classified as having overall early&#8208;stage diseases (T1&#8208;2&#8201;N0&#8208;1 M0). Among the cohort, 87 patients underwent HPV/p16 testing, of which 25 patients (28.7%) were identified as HPV/p16 positive. When compared to HPV/p16 negative patients, those who were HPV/p16 positive were significantly more likely to receive definitive radiotherapy (64.0% vs. 27.4%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004).</p></sec><sec id="hed28143-sec-0012"><label>3.2</label><title>Treatment Characteristics</title><p>Among the total patient cohort, 99 individuals (38.7%) underwent primary surgery, of which 36 subsequently received postoperative radiotherapy (PORT). Additionally, 148 patients (57.8%) were treated with definitive radiotherapy, with 30 of these patients having received induction chemotherapy prior to the radiotherapy. Induction chemotherapy was administered to patients presenting with clinical T2&#8208;4 stage tumors. Nine patients received palliative treatment due to advanced disease; the palliative treatment regimens included platinum&#8208;based therapies, paclitaxel&#8208;based therapies, or combinations thereof with either 5&#8208;fluorouracil or oral fluorouracil (capecitabine) chemotherapy.</p><p>In comparison to patients who underwent primary surgery, those in the definitive radiotherapy group exhibited a lower likelihood of having a prior history of cancer (<italic toggle="yes">p</italic>&#8201;=&#8201;0.034). Conversely, they demonstrated a higher likelihood of presenting with HPV/p16 positive disease (<italic toggle="yes">p</italic>&#8201;=&#8201;0.004), retropharyngeal lymph node involvement (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and advanced clinical T&#8208;stage disease (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec></sec><sec id="hed28143-sec-0013"><label>4</label><title>Survival Analysis</title><sec id="hed28143-sec-0014"><label>4.1</label><title>Oncological Outcomes Concerning Various Treatment Groups</title><p>The median follow&#8208;up duration for all patients was 52&#8201;months (range: 4&#8211;504&#8201;months), while for surviving patients, it was 68&#8201;months (range: 25&#8211;504&#8201;months). As of the last follow&#8208;up date, tumor progression was observed in 124 patients (48.4%), and 156 patients (60.9%) had died, including 112 patients (43.8%) who succumbed to disease&#8208;specific causes. The 5&#8208;year PFS, OS, and DSS for the entire cohort were 56.8%, 53.8%, and 61.4%, respectively. When analyzed by treatment modality, the 5&#8208;year PFS, OS, and DSS rates for patients who underwent primary surgery compared to those who received definitive radiotherapy were 68.6% versus 52.0% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003), 62.8% versus 52.8% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.038), and 72.5% versus 57.4% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.011), respectively. The Kaplan&#8211;Meier survival curves are presented in Figure&#160;<xref rid="hed28143-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="FIGURE" id="hed28143-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Kaplan&#8211;Meier survival curves stratified by treatment group. (A) Kaplan&#8211;Meier curve for PFS in the whole cohort stratified by treatment group. (B) Kaplan&#8211;Meier curve for OS in the whole cohort stratified by treatment group. (C) Kaplan&#8211;Meier curve for DSS in the whole cohort stratified by treatment group. (D) Kaplan&#8211;Meier curve for PFS in early&#8208;stage SCCSPs stratified by treatment group. (E) Kaplan&#8211;Meier curve for OS in early&#8208;stage SCCSPs stratified by treatment group. (F) Kaplan&#8211;Meier curve for DSS in early&#8208;stage SCCSPs stratified by treatment group. [Color figure can be viewed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="HED-47-2248-g001.jpg"/></fig><p>In the primary surgery cohort, univariate analysis indicated that patients who underwent PORT experienced significantly poorer PFS (5&#8208;year PFS: 50.9% vs. 79.5%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001), OS (5&#8208;year OS: 51.3% vs. 69.5%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.048), and DSS (5&#8208;year DSS: 57.0% vs. 82.0%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) in comparison to those who did not receive PORT (see Table&#160;<xref rid="hed28143-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="hed28143-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Univariate and multivariate analysis for the entire cohort.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Variable</th><th colspan="2" align="center" valign="bottom" rowspan="1">Univariate analysis</th><th colspan="2" align="center" valign="bottom" rowspan="1">Multivariate analysis (PFS)</th><th colspan="2" align="center" valign="bottom" rowspan="1">Univariate analysis</th><th colspan="2" align="center" valign="bottom" rowspan="1">Multivariate analysis (OS)</th><th colspan="2" align="center" valign="bottom" rowspan="1">Univariate analysis</th><th colspan="2" align="center" valign="bottom" rowspan="1">Multivariate analysis (DSS)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">5&#8201;years PFS (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">5&#8201;year OS (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">5&#8201;year DSS (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">whole cohort</td><td align="center" valign="top" rowspan="1" colspan="1">56.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">53.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.030</td><td align="center" valign="top" rowspan="1" colspan="1">1.03 (1.01&#8211;1.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (1.02&#8211;1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (1.02&#8211;1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.495</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.484</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.255</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">55.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">53.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">60.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">67.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">62.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">76.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoker</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.258</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.135</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.231</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">61.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">57.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">54.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">52.6</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drinker</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.768</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.160</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.415</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">57.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">56.3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">56.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">52.0</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous cancer</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.570</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.911</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.561</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">62.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">54.3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">56.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">52.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">62.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RN involved</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.339</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.812</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.714</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">56.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">54.1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">61.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">57.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">50.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">55.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV/p16 status</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.662</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.460</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.839</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">66.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">58.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">72.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">67.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">72.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">72.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cT stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.073</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1&#8208;2</td><td align="center" valign="top" rowspan="1" colspan="1">63.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">59.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">67.8</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T3&#8208;4</td><td align="center" valign="top" rowspan="1" colspan="1">35.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.76 (1.18&#8211;2.64)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">37.5</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.43 (0.97&#8211;2.10)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.6</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.65 (1.07&#8211;2.54)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cN stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.009</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N0&#8208;1</td><td align="center" valign="top" rowspan="1" colspan="1">65.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">60.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">69.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N2&#8208;3</td><td align="center" valign="top" rowspan="1" colspan="1">37.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.93 (1.31&#8211;2.85)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">38.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.62 (1.13&#8211;2.31)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">42.2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.09 (1.39&#8211;3.13)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall c&#8208;stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">I&#8208;III</td><td align="center" valign="top" rowspan="1" colspan="1">68.5</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">64.1</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">74.4</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">35.2</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">35.4</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">38.3</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Definitive RT</td><td align="center" valign="top" rowspan="1" colspan="1">52.0</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">52.8</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">57.4</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Ref</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary surgery</td><td align="center" valign="top" rowspan="1" colspan="1">68.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.68 (0.45&#8211;1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td><td align="center" valign="top" rowspan="1" colspan="1">62.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.54&#8211;1.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.172</td><td align="center" valign="top" rowspan="1" colspan="1">72.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.46&#8211;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Palliative</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">10.29 (4.16&#8211;25.45)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">27.80 (10.65&#8211;72.59)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">28.66 (10.13&#8211;81.06)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot id="hed28143-ntgp-0003"><fn id="hed28143-note-0004"><p>Abbreviations: CI, confidence interval; c&#8208;stage, clinical stage; HR, hazard ratio; ICT, induction therapy; RN, Retropharyngeal nodes; RT, radiotherapy.</p></fn></table-wrap-foot></table-wrap><p>In the definitive radiotherapy cohort, patients who underwent induction therapy did not demonstrate a statistically significant enhancement in PFS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.296), OS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.362), or DSS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.224). Additionally, we evaluated the prognostic implications of salvage surgery within this cohort. A total of 25 patients underwent salvage surgery due to residual locoregional disease or progression of locoregional disease. The results indicated that salvage surgery was associated with a statistically significant improvement in 5&#8208;year OS (74.3%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.023) and a near statistically significant enhancement in 5&#8208;year DSS (79.2%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.068).</p><p>In the multivariable analysis, no statistically significant differences were observed in PFS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.080), OS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.172), or DSS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.130) between patients who underwent primary surgery and those who received definitive radiotherapy (see Table&#160;<xref rid="hed28143-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="hed28143-sec-0015"><label>4.2</label><title>Treatment Outcomes for Early&#8208;Stage <styled-content style="fixed-case" toggle="no">SCCSPs</styled-content>
</title><p>We conducted a comparative analysis of treatment outcomes for a cohort of 141 patients (55.1%) with clinical early&#8208;stage tumors (cT1&#8208;2 N0&#8208;1 M0). The results indicated that primary surgical intervention yielded favorable 5&#8208;year PFS rates of 84.7%, OS rates of 74.5%, and DSS rates of 86.8% in this cohort. Multivariable survival analysis demonstrated that primary surgery, in contrast to definitive radiotherapy, was significantly associated with improved PFS (HR&#8201;=&#8201;0.37, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002), OS (HR&#8201;=&#8201;0.55, <italic toggle="yes">p</italic>&#8201;=&#8201;0.012), and DSS (HR&#8201;=&#8201;0.45, <italic toggle="yes">p</italic>&#8201;=&#8201;0.020). A summary of the survival outcomes is presented in Table&#160;<xref rid="hed28143-tbl-0003" ref-type="table">3</xref> and Figure&#160;<xref rid="hed28143-fig-0002" ref-type="fig">2</xref>.</p><table-wrap position="float" id="hed28143-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Multivariate analysis for early&#8208;stage (cT1&#8208;2&#8201;N0&#8208;1 M0) tumors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Variable</th><th colspan="2" align="center" valign="bottom" rowspan="1">PFS</th><th colspan="2" align="center" valign="bottom" rowspan="1">OS</th><th colspan="2" align="center" valign="bottom" rowspan="1">DSS</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, y</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.98&#8211;1.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.457</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (1.01&#8211;1.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td><td align="center" valign="top" rowspan="1" colspan="1">1.03 (0.99&#8211;1.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.141</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cT stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T2</td><td align="center" valign="top" rowspan="1" colspan="1">3.06 (1.53&#8211;6.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">1.31 (0.80&#8211;2.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.286</td><td align="center" valign="top" rowspan="1" colspan="1">2.57 (1.25&#8211;5.31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cN stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N1</td><td align="center" valign="top" rowspan="1" colspan="1">1.56 (0.78&#8211;3.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.210</td><td align="center" valign="top" rowspan="1" colspan="1">1.55 (0.84&#8211;2.84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.159</td><td align="center" valign="top" rowspan="1" colspan="1">1.64 (0.77&#8211;3.49)</td><td align="center" valign="top" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Definitive RT</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary surgery</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 (0.19&#8211;0.69)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.34&#8211;0.87)</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 (0.23&#8211;0.88)</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td></tr></tbody></table><table-wrap-foot id="hed28143-ntgp-0004"><fn id="hed28143-note-0005"><p>Abbreviations: CI, confidence interval; HR, hazard ratio; RT, radiotherapy.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="hed28143-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Kaplan&#8211;Meier survival curves stratified by HPV/p16 status. (A) Kaplan&#8211;Meier curve for PFS stratified by HPV/p16 status. (B) Kaplan&#8211;Meier curve for OS stratified by HPV/p16 status. (C) Kaplan&#8211;Meier curve for DSS stratified by HPV/p16 status. [Color figure can be viewed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="HED-47-2248-g002.jpg"/></fig></sec><sec id="hed28143-sec-0016"><label>4.3</label><title>Oncological Outcomes Concerning <styled-content style="fixed-case" toggle="no">HPV</styled-content>/p16 Status</title><p>Survival analyses were conducted on patients with known HPV/p16 status. In the univariate analysis, patients who were HPV/p16 positive exhibited survival rates comparable to those who were HPV/p16 negative. The 5&#8208;year PFS, OS, and DSS for patients with HPV/p16 positive disease compared to those with HPV/p16 negative disease were 67.8% versus 66.8% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.662), 72.8% versus 58.4% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.460), and 72.8% versus 72.5% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.839), respectively. The Kaplan&#8211;Meier survival curves are presented in Figure&#160;<xref rid="hed28143-fig-0002" ref-type="fig">2</xref>.</p></sec><sec id="hed28143-sec-0017"><label>4.4</label><title>Complications</title><p>In total, 19 out of 256 patients (7.4%) experienced severe complications. Among these, one patient developed postoperative pneumonia following surgery and subsequently succumbed to acute respiratory failure. The remaining 18 patients presented with one or more of the following severe complications: permanent feeding tube placement for nutritional support (9 patients), skin ulcer (5 patients), oral mucositis (4 patients), osteoradionecrosis (3 patients), and wound infection after a planned neck dissection that necessitated surgical debridement (1 patient).</p></sec></sec><sec sec-type="discussion" id="hed28143-sec-0018"><label>5</label><title>Discussion</title><p>There exists a limited number of studies that independently analyze SCCSP from the other oropharyngeal subsites. The current cohort represents one of the largest single&#8208;institution series documented in the literature to date. Our analysis demonstrated that primary is associated with enhanced oncological outcomes for patients with early&#8208;stage SCCSP. Furthermore, our findings did not support the prognostic significance of HPV status in SCCSP.</p><p>The baseline patient characteristics observed in this study are largely consistent with those documented in prior research. A significant majority (75.7%) of SCCSPs presented with early T&#8208;stage tumors (T1&#8208;2), which are readily identifiable during clinical examination. The distribution of age, as well as the proportions of smokers, alcohol consumers, patients with cancer history, early T&#8208;stage tumors, and early N&#8208;stage tumors (N0&#8208;1), align closely with findings reported in the existing literature [<xref rid="hed28143-bib-0004" ref-type="bibr">4</xref>, <xref rid="hed28143-bib-0009" ref-type="bibr">9</xref>, <xref rid="hed28143-bib-0010" ref-type="bibr">10</xref>, <xref rid="hed28143-bib-0011" ref-type="bibr">11</xref>, <xref rid="hed28143-bib-0012" ref-type="bibr">12</xref>]. However, it is noteworthy that our cohort exhibited a higher proportion of male patients, accounting for 91.0%.</p><p>It has been well established that patients with HPV&#8208;positive OPSCC typically present with an earlier onset age, improved performance status, reduced tobacco exposure rates, and heightened sensitivity to radiotherapy, resulting in a notably favorable prognosis [<xref rid="hed28143-bib-0002" ref-type="bibr">2</xref>, <xref rid="hed28143-bib-0013" ref-type="bibr">13</xref>, <xref rid="hed28143-bib-0014" ref-type="bibr">14</xref>, <xref rid="hed28143-bib-0015" ref-type="bibr">15</xref>]. However, similar characteristics were not observed in SCCSPs. The prevalence of HPV&#8208;positive disease (28.7%) in SCCSPs in the current study was significantly lower than that found in tonsillar&#8208;related OPSCCs. A summary of the prevalence of HPV/p16 positive disease in SCCSPs reported in the literature is presented in Table&#160;<xref rid="hed28143-tbl-0004" ref-type="table">4</xref>. In this study, HPV&#8208;positive SCCSPs exhibited comparable onset ages and similar proportions of positive smokers and drinkers when compared to HPV&#8208;negative SCCSPs. Furthermore, our results indicated that HPV status did not hold prognostic significance in SCCSPs. We found that the survival rates of SCCSPs, irrespective of HPV status, were analogous to those of HPV&#8208;negative tonsillar&#8208;related OPSCC [<xref rid="hed28143-bib-0003" ref-type="bibr">3</xref>, <xref rid="hed28143-bib-0042" ref-type="bibr">42</xref>]. These findings support the assertion that all other OPSCCs (carcinomas arising in the oropharynx outside the tonsils and base of the tongue) should be classified as HPV&#8208;negative OPSCC. Given the considerable research interest in de&#8208;escalating treatment for patients with HPV&#8208;positive OPSCC due to their excellent outcomes, it is imperative to consider the impact of oropharyngeal subsites in treatment planning to mitigate treatment&#8208;related toxicity.</p><table-wrap position="float" id="hed28143-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Prevalence of HPV/p16 positive SCCSP.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Author, year</th><th align="center" valign="bottom" rowspan="1" colspan="1">Country</th><th align="center" valign="bottom" rowspan="1" colspan="1">HPV/p16+ tumors</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total number</th><th align="center" valign="bottom" rowspan="1" colspan="1">HPV prevalence</th><th align="center" valign="bottom" rowspan="1" colspan="1">HPV detection</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Haeggblom et&#160;al., 2017 [<xref rid="hed28143-bib-0006" ref-type="bibr">6</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Review</td><td align="center" valign="top" rowspan="1" colspan="1">59</td><td align="center" valign="top" rowspan="1" colspan="1">488</td><td align="center" valign="top" rowspan="1" colspan="1">12.1%</td><td align="center" valign="top" rowspan="1" colspan="1">unknown</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rietbergen et&#160;al., 2013 [<xref rid="hed28143-bib-0016" ref-type="bibr">16</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">124</td><td align="center" valign="top" rowspan="1" colspan="1">7.3%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tham et&#160;al., 2019 [<xref rid="hed28143-bib-0017" ref-type="bibr">17</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">SEER</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">115</td><td align="center" valign="top" rowspan="1" colspan="1">24.3%</td><td align="center" valign="top" rowspan="1" colspan="1">unknown</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schache et&#160;al., 2016 [<xref rid="hed28143-bib-0018" ref-type="bibr">18</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">UK</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">88</td><td align="center" valign="top" rowspan="1" colspan="1">9.1%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR or ISH</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">The present study</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">87</td><td align="center" valign="top" rowspan="1" colspan="1">28.7%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wang et&#160;al., 2016 [<xref rid="hed28143-bib-0019" ref-type="bibr">19</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">6%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iyer et&#160;al., 2015 [<xref rid="hed28143-bib-0020" ref-type="bibr">20</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">17.4%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lamet al., 2015 [<xref rid="hed28143-bib-0021" ref-type="bibr">21</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">9.4%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rietbergen et&#160;al., 2012 [<xref rid="hed28143-bib-0022" ref-type="bibr">22</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nasman et&#160;al., 2013 [<xref rid="hed28143-bib-0023" ref-type="bibr">23</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Sweden</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">31.8%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lybak et&#160;al., 2016 [<xref rid="hed28143-bib-0024" ref-type="bibr">24</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Norway</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">23.8%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gillison et&#160;al., 2012 [<xref rid="hed28143-bib-0025" ref-type="bibr">25</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">40%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Saito et&#160;al., 2013 [<xref rid="hed28143-bib-0026" ref-type="bibr">26</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Japan</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">18.7%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cerezo et&#160;al., 2014 [<xref rid="hed28143-bib-0027" ref-type="bibr">27</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Spain</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">38.5%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schache et&#160;al., 2013 [<xref rid="hed28143-bib-0028" ref-type="bibr">28</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">UK</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">30.8%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Limbergen et&#160;al., 2014 [<xref rid="hed28143-bib-0029" ref-type="bibr">29</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Belgium</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Morbini et&#160;al., 2014 [<xref rid="hed28143-bib-0030" ref-type="bibr">30</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Italy</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">10%</td><td align="center" valign="top" rowspan="1" colspan="1">ISH</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kim et&#160;al., 2014 [<xref rid="hed28143-bib-0031" ref-type="bibr">31</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Korea</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">40%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jiang et&#160;al., 2015 [<xref rid="hed28143-bib-0032" ref-type="bibr">32</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">ISH</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kim et&#160;al., 2015 [<xref rid="hed28143-bib-0033" ref-type="bibr">33</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">South Korea</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">11.1%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ukpo et&#160;al., 2009 [<xref rid="hed28143-bib-0034" ref-type="bibr">34</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">37.5%</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Park et&#160;al., 2012 [<xref rid="hed28143-bib-0035" ref-type="bibr">35</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Korea</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">12.5%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">McIlwain et&#160;al., 2014 [<xref rid="hed28143-bib-0036" ref-type="bibr">36</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">66.7%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Davis et&#160;al., 2014 [<xref rid="hed28143-bib-0037" ref-type="bibr">37</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grisar et&#160;al., 2016 [<xref rid="hed28143-bib-0038" ref-type="bibr">38</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Belgium</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">20%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bahl et&#160;al., 2014 [<xref rid="hed28143-bib-0039" ref-type="bibr">39</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">India</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">PCR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bhosale et&#160;al., 2016 [<xref rid="hed28143-bib-0040" ref-type="bibr">40</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">India</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hoffmann et&#160;al., 2012 [<xref rid="hed28143-bib-0041" ref-type="bibr">41</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Germany</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">25%</td><td align="center" valign="top" rowspan="1" colspan="1">p16 IHC and PCR or ISH</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">167</td><td align="center" valign="top" rowspan="1" colspan="1">1162</td><td align="center" valign="top" rowspan="1" colspan="1">14.4%</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>Prior research has demonstrated satisfactory locoregional control rates and cause&#8208;specific survival in patients with SCCSPs who underwent definitive radiotherapy; however, the overall 5&#8208;year OS was approximately 40% [<xref rid="hed28143-bib-0009" ref-type="bibr">9</xref>, <xref rid="hed28143-bib-0010" ref-type="bibr">10</xref>]. In the current study, the 5&#8208;year OS rate for patients receiving definitive radiotherapy was significantly improved at 52.8%. Furthermore, we observed that patients who underwent salvage surgery exhibited favorable OS and DSS rates. The implementation of salvage surgery may have contributed to the enhanced outcomes observed in our study. Additionally, our findings indicated excellent outcomes for patients treated with primary surgery, with the 5&#8208;year DSS comparable to the results reported by Iyer et&#160;al., which included a cohort of 150 patients treated with primary surgical intervention [<xref rid="hed28143-bib-0011" ref-type="bibr">11</xref>]. The 5&#8208;year PFS rate of 52.0% and OS rate of 52.8% for the entire cohort in this study are notably superior to the outcomes reported by Schernberg et&#160;al. Notably, a higher proportion (39.8%) of patients in the present cohort received surgical treatment. Given that primary surgery yielded satisfactory outcomes, we hypothesize that the favorable results observed in the primary surgery group may have contributed to the overall improved outcomes for the entire cohort in this study.</p><p>The findings of our study hold significant implications for the management of SCCSP. Patients with early&#8208;stage disease exhibit an excellent prognosis when treated with primary surgery. As such, our results may provide a rational basis for reconsidering the management strategies for early&#8208;stage SCCSP, advocating a transition from nonsurgical approaches to transoral robotic surgery (TORS). Existing literature indicates that TORS is associated with enhanced surgical outcomes and improved survival rates, accompanied by a minimal risk of severe complications in the treatment of early&#8208;stage OPSCC [<xref rid="hed28143-bib-0043" ref-type="bibr">43</xref>, <xref rid="hed28143-bib-0044" ref-type="bibr">44</xref>, <xref rid="hed28143-bib-0045" ref-type="bibr">45</xref>, <xref rid="hed28143-bib-0046" ref-type="bibr">46</xref>, <xref rid="hed28143-bib-0047" ref-type="bibr">47</xref>]. The ORATOR trial, a randomized phase II study, compared primary radiotherapy with primary TORS and neck dissection for early&#8208;stage OPSCC. The findings revealed that while patients receiving radiotherapy demonstrated superior scores on the MD Anderson Dysphagia Inventory (MDADI), the difference decreased with time and never reached a threshold. Importantly, post hoc subgroup analysis of patients with palatine tonsil primaries indicated no significant difference in MDADI scores between those undergoing surgical versus nonsurgical treatment [<xref rid="hed28143-bib-0048" ref-type="bibr">48</xref>, <xref rid="hed28143-bib-0049" ref-type="bibr">49</xref>, <xref rid="hed28143-bib-0050" ref-type="bibr">50</xref>]. However, comparative research examining outcomes between SCCSP patients treated with TORS and those receiving non&#8208;TORS therapies remains limited. Given the favorable oncological outcomes associated with TORS and its suitability for early&#8208;stage SCCSP, we propose that TORS may emerge as the preferred treatment modality for early&#8208;stage SCCSP in the future, although further validation is warranted.</p><p>There are several limitations due to the retrospective nature of this study. First, a large number of patients lack information about tumor HPV status or p16 expression level. Our analysis of the prognostic role of HPV/p16 status was based on a relatively small sample size; further research with larger and more diverse populations is necessary to establish the reliability and validity of our findings. Second, this study primarily focused on the oncological outcomes of various treatment modalities and did not include functional assessments of swallowing and speech due to insufficient data. Lastly, as a retrospective study, it is inherently subject to the limitations typical of this type of research.</p></sec><sec sec-type="conclusions" id="hed28143-sec-0019"><label>6</label><title>Conclusions</title><p>SCCSPs exhibit characteristics that are more similar to those arising in the oral cavity than to those associated with tonsillar&#8208;related OPSCCs. HPV status does not have prognostic significance for SCCSP. In patients with early&#8208;stage SCCSP, surgery yields a more favorable oncological outcome.</p></sec><sec sec-type="COI-statement" id="hed28143-sec-0020"><title>Conflicts of Interest</title><p>
<mml:math id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>The authors declare</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">no</mml:mi><mml:mspace width="0.25em"/><mml:mtext>conflicts of interest</mml:mtext><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math>
</p></sec></body><back><sec sec-type="data-availability" id="hed28143-sec-0022"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="hed28143-bibl-0001"><title>References</title><ref id="hed28143-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="hed28143-cit-0001"><string-name name-style="western"><given-names>A. C.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Day</surname></string-name>, and <string-name name-style="western"><given-names>B. W.</given-names><surname>Neville</surname></string-name>, &#8220;<article-title>Oral Cavity and Oropharyngeal Squamous Cell Carcinoma&#8212;An Update</article-title>,&#8221; <source>CA: a Cancer Journal for Clinicians</source><volume>65</volume> (<year>2015</year>): <fpage>401</fpage>&#8211;<lpage>421</lpage>.<pub-id pub-id-type="pmid">26215712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21293</pub-id></mixed-citation></ref><ref id="hed28143-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hed28143-cit-0002"><string-name name-style="western"><given-names>T. D.</given-names><surname>Ellington</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Henley</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Senkomago</surname></string-name>, et&#160;al., &#8220;<article-title>Trends in Incidence of Cancers of the Oral Cavity and Pharynx &#8208; United States 2007&#8208;2016</article-title>,&#8221; <source>Mmwr&#8208;Morbidity and Mortality Weekly Report</source><volume>69</volume> (<year>2020</year>): <fpage>433</fpage>&#8211;<lpage>438</lpage>.<pub-id pub-id-type="pmid">32298244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6915a1</pub-id><pub-id pub-id-type="pmcid">PMC7755056</pub-id></mixed-citation></ref><ref id="hed28143-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hed28143-cit-0003"><string-name name-style="western"><given-names>T.</given-names><surname>Tham</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ahn</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Frank</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kraus</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Costantino</surname></string-name>, &#8220;<article-title>Anatomical Subsite Modifies Survival in Oropharyngeal Squamous Cell Carcinoma: National Cancer Database Study</article-title>,&#8221; <source>Head &amp; Neck</source><volume>42</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>434</fpage>&#8211;<lpage>445</lpage>, <pub-id pub-id-type="doi">10.1002/hed.26019</pub-id>.<pub-id pub-id-type="pmid">31773842</pub-id></mixed-citation></ref><ref id="hed28143-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="hed28143-cit-0004"><string-name name-style="western"><given-names>C. K.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>A. Y.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Alonso</surname></string-name>, et&#160;al., &#8220;<article-title>Squamous Cell Carcinoma of the Soft Palate in the United States: A Population&#8208;Based Study</article-title>,&#8221; <source>Otolaryngology&#8211;Head and Neck Surgery</source><volume>159</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>662</fpage>&#8211;<lpage>668</lpage>, <pub-id pub-id-type="doi">10.1177/0194599818771931</pub-id>.<pub-id pub-id-type="pmid">29734872</pub-id></mixed-citation></ref><ref id="hed28143-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="hed28143-cit-0005"><string-name name-style="western"><given-names>E.</given-names><surname>Gelwan</surname></string-name>, <string-name name-style="western"><given-names>I.&#8208;J.</given-names><surname>Malm</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Khararjian</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Fakhry</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Bishop</surname></string-name>, and <string-name name-style="western"><given-names>W. H.</given-names><surname>Westra</surname></string-name>, &#8220;<article-title>Nonuniform Distribution of High&#8208;Risk Human Papillomavirus in Squamous Cell Carcinomas of the Oropharynx: Rethinking the Anatomic Boundaries of Oral and Oropharyngeal Carcinoma From an Oncologic HPV Perspective</article-title>,&#8221; <source>American Journal of Surgical Pathology</source><volume>41</volume> (<year>2017</year>): <fpage>1722</fpage>&#8211;<lpage>1728</lpage>.<pub-id pub-id-type="pmid">28877058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000000929</pub-id></mixed-citation></ref><ref id="hed28143-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="hed28143-cit-0006"><string-name name-style="western"><given-names>L.</given-names><surname>Haeggblom</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ramqvist</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tommasino</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Dalianis</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>N&#228;sman</surname></string-name>, &#8220;<article-title>Time to Change Perspectives on HPV in Oropharyngeal Cancer. A Systematic Review of HPV Prevalence per Oropharyngeal Sub&#8208;Site the Last 3&#8201;Years</article-title>,&#8221; <source>Papillomavirus Research</source><volume>4</volume> (<year>2017</year>): <fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29179862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pvr.2017.05.002</pub-id><pub-id pub-id-type="pmcid">PMC5883233</pub-id></mixed-citation></ref><ref id="hed28143-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="hed28143-cit-0007"><string-name name-style="western"><given-names>Y.</given-names><surname>Monnier</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Simon</surname></string-name>, &#8220;<article-title>Surgery Versus Radiotherapy for Early Oropharyngeal Tumors: A Never&#8208;Ending Debate</article-title>,&#8221; <source>Current Treatment Options in Oncology</source><volume>16</volume> (<year>2015</year>): <fpage>42</fpage>.<pub-id pub-id-type="pmid">26187797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11864-015-0362-4</pub-id></mixed-citation></ref><ref id="hed28143-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hed28143-cit-0008"><string-name name-style="western"><given-names>C.</given-names><surname>Ndiaye</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mena</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Alemany</surname></string-name>, et&#160;al., &#8220;<article-title>HPV DNA, E6/E7 mRNA, and p16 <sup>INK4a</sup> Detection in Head and Neck Cancers: A Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Lancet Oncology</source><volume>15</volume> (<year>2014</year>): <fpage>1319</fpage>&#8211;<lpage>1331</lpage>.<pub-id pub-id-type="pmid">25439690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)70471-1</pub-id></mixed-citation></ref><ref id="hed28143-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hed28143-cit-0009"><string-name name-style="western"><given-names>A.</given-names><surname>Schernberg</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Canova</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Blanchard</surname></string-name>, et&#160;al., &#8220;<article-title>Prognostic Factors in Patients With Soft Palate Squamous Cell Carcinoma</article-title>,&#8221; <source>Head &amp; Neck</source><volume>41</volume> (<year>2019</year>): <fpage>1441</fpage>&#8211;<lpage>1449</lpage>.<pub-id pub-id-type="pmid">30636178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.25598</pub-id></mixed-citation></ref><ref id="hed28143-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hed28143-cit-0010"><string-name name-style="western"><given-names>C. T.</given-names><surname>Rapp</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Chera</surname></string-name>, <string-name name-style="western"><given-names>C. G.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Amdur</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Kirwan</surname></string-name>, and <string-name name-style="western"><given-names>W. M.</given-names><surname>Mendenhall</surname></string-name>, &#8220;<article-title>Radiation Treatment of Soft Palate Squamous Cell Carcinoma</article-title>,&#8221; <source>Head &amp; Neck</source><volume>42</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>530</fpage>&#8211;<lpage>538</lpage>, <pub-id pub-id-type="doi">10.1002/hed.26035</pub-id>.<pub-id pub-id-type="pmid">31773865</pub-id></mixed-citation></ref><ref id="hed28143-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="hed28143-cit-0011"><string-name name-style="western"><given-names>N. G.</given-names><surname>Iyer</surname></string-name>, <string-name name-style="western"><given-names>I. J.</given-names><surname>Nixon</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Palmer</surname></string-name>, et&#160;al., &#8220;<article-title>Surgical Management of Squamous Cell Carcinoma of the Soft Palate: Factors Predictive of Outcome</article-title>,&#8221; <source>Head &amp; Neck</source><volume>34</volume>, no. <issue>8</issue> (<year>2011</year>): <fpage>1071</fpage>&#8211;<lpage>1080</lpage>, <pub-id pub-id-type="doi">10.1002/hed.21878</pub-id>.<pub-id pub-id-type="pmid">22109978</pub-id></mixed-citation></ref><ref id="hed28143-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hed28143-cit-0012"><string-name name-style="western"><given-names>B. S.</given-names><surname>Chera</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Amdur</surname></string-name>, <string-name name-style="western"><given-names>R. W.</given-names><surname>Hinerman</surname></string-name>, et&#160;al., &#8220;<article-title>Definitive Radiation Therapy for Squamous Cell Carcinoma of the Soft Palate</article-title>,&#8221; <source>Head &amp; Neck</source><volume>30</volume> (<year>2008</year>): <fpage>1114</fpage>&#8211;<lpage>1119</lpage>.<pub-id pub-id-type="pmid">18615732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.20848</pub-id></mixed-citation></ref><ref id="hed28143-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hed28143-cit-0013"><string-name name-style="western"><given-names>M. L.</given-names><surname>Gillison</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>D'Souza</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Westra</surname></string-name>, et&#160;al., &#8220;<article-title>Distinct Risk Factor Profiles for Human Papillomavirus Type 16&#8208;Positive and Human Papillomavirus Type 16&#8208;Negative Head and Neck Cancers</article-title>,&#8221; <source>Jnci&#8208;Journal of the National Cancer Institute</source><volume>100</volume> (<year>2008</year>): <fpage>407</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djn025</pub-id><pub-id pub-id-type="pmid">18334711</pub-id></mixed-citation></ref><ref id="hed28143-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="hed28143-cit-0014"><string-name name-style="western"><given-names>C.</given-names><surname>Fakhry</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Westra</surname></string-name>, <string-name name-style="western"><given-names>S. L. A.</given-names><surname>Cmelak</surname></string-name>, et&#160;al., &#8220;<article-title>Improved Survival of Patients With Human Papillomavirus&#8208;Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial</article-title>,&#8221; <source>Jnci&#8208;Journal of the National Cancer Institute</source><volume>100</volume> (<year>2008</year>): <fpage>261</fpage>&#8211;<lpage>269</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djn011</pub-id><pub-id pub-id-type="pmid">18270337</pub-id></mixed-citation></ref><ref id="hed28143-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hed28143-cit-0015"><string-name name-style="western"><given-names>S. H.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Waldron</surname></string-name>, et&#160;al., &#8220;<article-title>Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus&#8208;Related Oropharyngeal Carcinomas</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>33</volume>, no. <issue>8</issue> (<year>2015</year>): <fpage>836</fpage>&#8211;<lpage>845</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2014.58.6412</pub-id>.<pub-id pub-id-type="pmid">25667292</pub-id></mixed-citation></ref><ref id="hed28143-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="hed28143-cit-0016"><string-name name-style="western"><given-names>M. M.</given-names><surname>Rietbergen</surname></string-name>, <string-name name-style="western"><given-names>R. H.</given-names><surname>Brakenhoff</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Bloemena</surname></string-name>, et&#160;al., &#8220;<article-title>Human Papillomavirus Detection and Comorbidity: Critical Issues in Selection of Patients With Oropharyngeal Cancer for Treatment De&#8208;Escalation Trials</article-title>,&#8221; <source>Annals of Oncology</source><volume>24</volume> (<year>2013</year>): <fpage>2740</fpage>&#8211;<lpage>2745</lpage>.<pub-id pub-id-type="pmid">23946330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdt319</pub-id></mixed-citation></ref><ref id="hed28143-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hed28143-cit-0017"><string-name name-style="western"><given-names>T.</given-names><surname>Tham</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wotman</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Roche</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kraus</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Costantino</surname></string-name>, &#8220;<article-title>The Prognostic Effect of Anatomic Subsite in HPV&#8208;Positive Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>American Journal of Otolaryngology</source><volume>40</volume> (<year>2019</year>): <fpage>567</fpage>&#8211;<lpage>572</lpage>.<pub-id pub-id-type="pmid">31113681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjoto.2019.05.006</pub-id></mixed-citation></ref><ref id="hed28143-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="hed28143-cit-0018"><string-name name-style="western"><given-names>A. G.</given-names><surname>Schache</surname></string-name>, <string-name name-style="western"><given-names>N. G.</given-names><surname>Powell</surname></string-name>, <string-name name-style="western"><given-names>K. S.</given-names><surname>Cuschieri</surname></string-name>, et&#160;al., &#8220;<article-title>HPV&#8208;Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology</article-title>,&#8221; <source>Cancer Research</source><volume>76</volume> (<year>2016</year>): <fpage>6598</fpage>&#8211;<lpage>6606</lpage>.<pub-id pub-id-type="pmid">27569214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-16-0633</pub-id><pub-id pub-id-type="pmcid">PMC9158514</pub-id></mixed-citation></ref><ref id="hed28143-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="hed28143-cit-0019"><string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>R.&#8208;H.</given-names><surname>Xia</surname></string-name>, <string-name name-style="western"><given-names>D.&#8208;X.</given-names><surname>Ye</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population</article-title>,&#8221; <source>PLoS One</source><volume>11</volume>, no. <issue>10</issue> (<year>2016</year>): <elocation-id>e0164491</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0164491</pub-id>.<pub-id pub-id-type="pmid">27749915</pub-id><pub-id pub-id-type="pmcid">PMC5066983</pub-id></mixed-citation></ref><ref id="hed28143-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hed28143-cit-0020"><string-name name-style="western"><given-names>N. G.</given-names><surname>Iyer</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dogan</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Palmer</surname></string-name>, et&#160;al., &#8220;<article-title>Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV&#8208;Positive and Negative Oropharyngeal Cancer</article-title>,&#8221; <source>Annals of Surgical Oncology</source><volume>22</volume> (<year>2015</year>): <fpage>4411</fpage>&#8211;<lpage>4421</lpage>.<pub-id pub-id-type="pmid">25801358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-015-4525-0</pub-id><pub-id pub-id-type="pmcid">PMC4986601</pub-id></mixed-citation></ref><ref id="hed28143-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hed28143-cit-0021"><string-name name-style="western"><given-names>E. W. H.</given-names><surname>Lam</surname></string-name>, <string-name name-style="western"><given-names>J. Y. W.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>A. B. W.</given-names><surname>Chan</surname></string-name>, et&#160;al., &#8220;<article-title>Prevalence, Clinicopathological Characteristics, and Outcome of Human Papillomavirus&#8208;Associated Oropharyngeal Cancer in Southern Chinese Patients</article-title>,&#8221; <source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>25</volume> (<year>2016</year>): <fpage>165</fpage>&#8211;<lpage>173</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-15-0869</pub-id><pub-id pub-id-type="pmid">26604268</pub-id></mixed-citation></ref><ref id="hed28143-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hed28143-cit-0022"><string-name name-style="western"><given-names>M. M.</given-names><surname>Rietbergen</surname></string-name>, <string-name name-style="western"><given-names>C. R.</given-names><surname>Leemans</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Bloemena</surname></string-name>, et&#160;al., &#8220;<article-title>Increasing Prevalence Rates of HPV Attributable Oropharyngeal Squamous Cell Carcinomas in The Netherlands as Assessed by a Validated Test Algorithm</article-title>,&#8221; <source>International Journal of Cancer</source><volume>132</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>1565</fpage>&#8211;<lpage>1571</lpage>, <pub-id pub-id-type="doi">10.1002/ijc.27821</pub-id>.<pub-id pub-id-type="pmid">22949073</pub-id></mixed-citation></ref><ref id="hed28143-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="hed28143-cit-0023"><string-name name-style="western"><given-names>A.</given-names><surname>Nasman</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Andersson</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Marklund</surname></string-name>, et&#160;al., &#8220;<article-title>HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome</article-title>,&#8221; <source>PLoS One</source><volume>8</volume> (<year>2013</year>): <elocation-id>e77025</elocation-id>.<pub-id pub-id-type="pmid">24130830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0077025</pub-id><pub-id pub-id-type="pmcid">PMC3794938</pub-id></mixed-citation></ref><ref id="hed28143-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="hed28143-cit-0024"><string-name name-style="western"><given-names>S.</given-names><surname>Lybak</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Lj&#248;kjel</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Haave</surname></string-name>, <string-name name-style="western"><given-names>&#192;.</given-names><surname>Karlsdottir</surname></string-name>, <string-name name-style="western"><given-names>O. K.</given-names><surname>Vintermyr</surname></string-name>, and <string-name name-style="western"><given-names>H. J.</given-names><surname>Aarstad</surname></string-name>, &#8220;<article-title>Primary Surgery Results in no Survival Benefit Compared to Primary Radiation for Oropharyngeal Cancer Patients Stratified by High&#8208;Risk Human Papilloma Virus Status</article-title>,&#8221; <source>European Archives of Oto&#8208;Rhino&#8208;Laryngology</source><volume>274</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>477</fpage>&#8211;<lpage>487</lpage>, <pub-id pub-id-type="doi">10.1007/s00405-016-4203-2</pub-id>.<pub-id pub-id-type="pmid">27491318</pub-id></mixed-citation></ref><ref id="hed28143-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hed28143-cit-0025"><string-name name-style="western"><given-names>M. L.</given-names><surname>Gillison</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jordan</surname></string-name>, et&#160;al., &#8220;<article-title>Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16&#8208;Positive and p16&#8208;Negative Oropharyngeal Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>30</volume> (<year>2012</year>): <fpage>2102</fpage>&#8211;<lpage>2111</lpage>.<pub-id pub-id-type="pmid">22565003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.38.4099</pub-id><pub-id pub-id-type="pmcid">PMC3397696</pub-id></mixed-citation></ref><ref id="hed28143-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="hed28143-cit-0026"><string-name name-style="western"><given-names>Y.</given-names><surname>Saito</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yoshida</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ushiku</surname></string-name>, et&#160;al., &#8220;<article-title>Prognostic Value of p16 Expression and Alcohol Consumption in Japanese Patients With Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>Cancer</source><volume>119</volume> (<year>2013</year>): <fpage>2005</fpage>&#8211;<lpage>2011</lpage>.<pub-id pub-id-type="pmid">23504914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.28015</pub-id></mixed-citation></ref><ref id="hed28143-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="hed28143-cit-0027"><string-name name-style="western"><given-names>L.</given-names><surname>Cerezo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>de la Torre</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Herv&#225;s</surname></string-name>, et&#160;al., &#8220;<article-title>Oropharyngeal Cancer Related to Human Papilloma Virus: Incidence and Prognosis in Madrid, Spain</article-title>,&#8221; <source>Clinical and Translational Oncology</source><volume>16</volume>, no. <issue>3</issue> (<year>2013</year>): <fpage>301</fpage>&#8211;<lpage>306</lpage>, <pub-id pub-id-type="doi">10.1007/s12094-013-1074-5</pub-id>.<pub-id pub-id-type="pmid">23828503</pub-id></mixed-citation></ref><ref id="hed28143-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="hed28143-cit-0028"><string-name name-style="western"><given-names>A. G.</given-names><surname>Schache</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Liloglou</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Risk</surname></string-name>, et&#160;al., &#8220;<article-title>Validation of a Novel Diagnostic Standard in HPV&#8208;Positive Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>British Journal of Cancer</source><volume>108</volume> (<year>2013</year>): <fpage>1332</fpage>&#8211;<lpage>1339</lpage>.<pub-id pub-id-type="pmid">23412100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2013.63</pub-id><pub-id pub-id-type="pmcid">PMC3619267</pub-id></mixed-citation></ref><ref id="hed28143-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="hed28143-cit-0029"><string-name name-style="western"><given-names>E. J.</given-names><surname>Van Limbergen</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Dok</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Laenen</surname></string-name>, et&#160;al., &#8220;<article-title>HPV&#8208;Related Oropharyngeal Cancers in Flanders (Belgium): A Multicenter Study</article-title>,&#8221; <source>B&#8208;ENT</source><volume>10</volume> (<year>2014</year>): <fpage>7</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">24765823</pub-id></mixed-citation></ref><ref id="hed28143-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="hed28143-cit-0030"><string-name name-style="western"><given-names>P.</given-names><surname>Morbini</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Alberizzi</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Tinelli</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of Transcriptionally Active HPV Infection in Formalin&#8208;Fixed, Paraffin&#8208;Embedded Biopsies of Oropharyngeal Carcinoma</article-title>,&#8221; <source>Human Pathology</source><volume>46</volume> (<year>2015</year>): <fpage>681</fpage>&#8211;<lpage>689</lpage>.<pub-id pub-id-type="pmid">25708613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humpath.2014.12.014</pub-id></mixed-citation></ref><ref id="hed28143-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="hed28143-cit-0031"><string-name name-style="western"><given-names>M.&#8208;J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M.&#8208;S.</given-names><surname>Ki</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kim</surname></string-name>, et&#160;al., &#8220;<article-title>Different Protein Expression Associated With Chemotherapy Response in Oropharyngeal Cancer According to HPV Status</article-title>,&#8221; <source>BMC Cancer</source><volume>14</volume> (<year>2014</year>): <elocation-id>824</elocation-id>, <pub-id pub-id-type="doi">10.1186/1471-2407-14-824</pub-id>.<pub-id pub-id-type="pmid">25380690</pub-id><pub-id pub-id-type="pmcid">PMC4232654</pub-id></mixed-citation></ref><ref id="hed28143-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="hed28143-cit-0032"><string-name name-style="western"><given-names>R.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Ekshyyan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Moore&#8208;Medlin</surname></string-name>, et&#160;al., &#8220;<article-title>Association Between Human Papilloma Virus/Epstein&#8211;Barr Virus Coinfection and Oral Carcinogenesis</article-title>,&#8221; <source>Journal of Oral Pathology &amp; Medicine</source><volume>44</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>28</fpage>&#8211;<lpage>36</lpage>, <pub-id pub-id-type="doi">10.1111/jop.12221</pub-id>.<pub-id pub-id-type="pmid">25040496</pub-id><pub-id pub-id-type="pmcid">PMC4286485</pub-id></mixed-citation></ref><ref id="hed28143-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="hed28143-cit-0033"><string-name name-style="western"><given-names>H. S.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>J. Y.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Lim</surname></string-name>, et&#160;al., &#8220;<article-title>Association Between PD&#8208;L1 and HPV Status and the Prognostic Value of PD&#8208;L1 in Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>Cancer Research and Treatment</source><volume>48</volume> (<year>2016</year>): <fpage>527</fpage>&#8211;<lpage>536</lpage>.<pub-id pub-id-type="pmid">26511814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2015.249</pub-id><pub-id pub-id-type="pmcid">PMC4843713</pub-id></mixed-citation></ref><ref id="hed28143-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="hed28143-cit-0034"><string-name name-style="western"><given-names>O. C.</given-names><surname>Ukpo</surname></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Pritchett</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Lewis</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Weaver</surname></string-name>, <string-name name-style="western"><given-names>D. I.</given-names><surname>Smith</surname></string-name>, and <string-name name-style="western"><given-names>E. J.</given-names><surname>Moore</surname></string-name>, &#8220;<article-title>Human Papillomavirus&#8208;Associated Oropharyngeal Squamous Cell Carcinomas: Primary Tumor Burden and Survival in Surgical Patients</article-title>,&#8221; <source>Annals of Otology, Rhinology, and Laryngology</source><volume>118</volume>, no. <issue>5</issue> (<year>2009</year>): <fpage>368</fpage>&#8211;<lpage>373</lpage>, <pub-id pub-id-type="doi">10.1177/000348940911800509</pub-id>.<pub-id pub-id-type="pmid">19548387</pub-id></mixed-citation></ref><ref id="hed28143-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="hed28143-cit-0035"><string-name name-style="western"><given-names>W. S.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ryu</surname></string-name>, <string-name name-style="western"><given-names>K. H.</given-names><surname>Cho</surname></string-name>, et&#160;al., &#8220;<article-title>Human Papillomavirus in Oropharyngeal Squamous Cell Carcinomas in Korea: Use of G1 Cycle Markers as New Prognosticators</article-title>,&#8221; <source>Head &amp; Neck</source><volume>34</volume>, no. <issue>10</issue> (<year>2011</year>): <fpage>1408</fpage>&#8211;<lpage>1417</lpage>, <pub-id pub-id-type="doi">10.1002/hed.21939</pub-id>.<pub-id pub-id-type="pmid">22052559</pub-id></mixed-citation></ref><ref id="hed28143-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="hed28143-cit-0036"><string-name name-style="western"><given-names>W. R.</given-names><surname>McIlwain</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Sood</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Nguyen</surname></string-name>, and <string-name name-style="western"><given-names>T. A.</given-names><surname>Day</surname></string-name>, &#8220;<article-title>Initial Symptoms in Patients With HPV&#8208;Positive and HPV&#8208;Negative Oropharyngeal Cancer</article-title>,&#8221; <source>JAMA Otolaryngology. Head &amp; Neck Surgery</source><volume>140</volume>, no. <issue>5</issue> (<year>2014</year>): <fpage>441</fpage>, <pub-id pub-id-type="doi">10.1001/jamaoto.2014.141</pub-id>.<pub-id pub-id-type="pmid">24652023</pub-id></mixed-citation></ref><ref id="hed28143-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="hed28143-cit-0037"><string-name name-style="western"><given-names>K. S.</given-names><surname>Davis</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Vargo</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Ferris</surname></string-name>, et&#160;al., &#8220;<article-title>Stereotactic Body Radiotherapy for Recurrent Oropharyngeal Cancer&#8212;Influence of HPV Status and Smoking History</article-title>,&#8221; <source>Oral Oncology</source><volume>50</volume> (<year>2014</year>): <fpage>1104</fpage>&#8211;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">25175942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2014.08.004</pub-id><pub-id pub-id-type="pmcid">PMC4505797</pub-id></mixed-citation></ref><ref id="hed28143-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="hed28143-cit-0038"><string-name name-style="western"><given-names>K.</given-names><surname>Grisar</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Dok</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Schoenaers</surname></string-name>, et&#160;al., &#8220;<article-title>Differences in Human Papillomavirus&#8208;Positive and &#8208;Negative Head and Neck Cancers in Belgium: An 8&#8208;Year Retrospective, Comparative Study</article-title>,&#8221; <source>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</source><volume>121</volume> (<year>2016</year>): <fpage>456</fpage>&#8211;<lpage>460</lpage>.<pub-id pub-id-type="pmid">26795451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oooo.2015.10.035</pub-id></mixed-citation></ref><ref id="hed28143-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="hed28143-cit-0039"><string-name name-style="western"><given-names>A.</given-names><surname>Bahl</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Kumar</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Dar</surname></string-name>, et&#160;al., &#8220;<article-title>Prevalence and Trends of Human Papillomavirus in Oropharyngeal Cancer in a Predominantly North Indian Population</article-title>,&#8221; <source>Head &amp; Neck</source><volume>36</volume>, no. <issue>4</issue> (<year>2013</year>): <fpage>505</fpage>&#8211;<lpage>510</lpage>, <pub-id pub-id-type="doi">10.1002/hed.23317</pub-id>.<pub-id pub-id-type="pmid">23729189</pub-id></mixed-citation></ref><ref id="hed28143-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="hed28143-cit-0040"><string-name name-style="western"><given-names>P. G.</given-names><surname>Bhosale</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pandey</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Desai</surname></string-name>, et&#160;al., &#8220;<article-title>Low Prevalence of Transcriptionally Active Human Papilloma Virus in Indian Patients With HNSCC and Leukoplakia</article-title>,&#8221; <source>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</source><volume>122</volume> (<year>2016</year>): <fpage>609</fpage>&#8211;<lpage>618.e7</lpage>.<pub-id pub-id-type="pmid">27765330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oooo.2016.06.006</pub-id></mixed-citation></ref><ref id="hed28143-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="hed28143-cit-0041"><string-name name-style="western"><given-names>M.</given-names><surname>Hoffmann</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Tribius</surname></string-name>, <string-name name-style="western"><given-names>E. S.</given-names><surname>Quabius</surname></string-name>, et&#160;al., &#8220;<article-title>HPV DNA, E6*I&#8208;mRNA Expression and p16INK4A Immunohistochemistry in Head and Neck Cancer&#8212;How Valid Is p16INK4A as Surrogate Marker?</article-title>,&#8221; <source>Cancer Letters</source><volume>323</volume> (<year>2012</year>): <fpage>88</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">22484467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2012.03.033</pub-id></mixed-citation></ref><ref id="hed28143-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="hed28143-cit-0042"><string-name name-style="western"><given-names>L.</given-names><surname>Marklund</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Holzhauser</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>de Flon</surname></string-name>, et&#160;al., &#8220;<article-title>Survival of Patients With Oropharyngeal Squamous Cell Carcinomas (OPSCC) in Relation to TNM 8&#8212;Risk of Incorrect Downstaging of HPV&#8208;Mediated Non&#8208;tonsillar, Non&#8208;Base of Tongue Carcinomas</article-title>,&#8221; <source>European Journal of Cancer</source><volume>139</volume> (<year>2020</year>): <fpage>192</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">32951963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2020.08.003</pub-id></mixed-citation></ref><ref id="hed28143-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="hed28143-cit-0043"><string-name name-style="western"><given-names>C. A.</given-names><surname>Bollig</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Morris</surname></string-name>, and <string-name name-style="western"><given-names>V. C.</given-names><surname>Stubbs</surname></string-name>, &#8220;<article-title>Transoral Robotic Surgery With Neck Dissection Versus Nonsurgical Treatment in Stage I and II Human Papillomavirus&#8208;Negative Oropharyngeal Cancer</article-title>,&#8221; <source>Head &amp; Neck</source><volume>44</volume> (<year>2022</year>): <fpage>1545</fpage>&#8211;<lpage>1553</lpage>.<pub-id pub-id-type="pmid">35365915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.27045</pub-id><pub-id pub-id-type="pmcid">PMC9324989</pub-id></mixed-citation></ref><ref id="hed28143-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="hed28143-cit-0044"><string-name name-style="western"><given-names>Y.</given-names><surname>Chillakuru</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Benito</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Strum</surname></string-name>, et&#160;al., &#8220;<article-title>Transoral Robotic Surgery Versus Nonrobotic Resection of Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>Head &amp; Neck</source><volume>43</volume> (<year>2021</year>): <fpage>2259</fpage>&#8211;<lpage>2273</lpage>.<pub-id pub-id-type="pmid">33899949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.26724</pub-id></mixed-citation></ref><ref id="hed28143-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="hed28143-cit-0045"><string-name name-style="western"><given-names>J. R.</given-names><surname>Kelly</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>An</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Survival Outcomes Among Human Papillomavirus&#8211;Negative cT1&#8208;2 N1&#8208;2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy</article-title>,&#8221; <source>JAMA Oncology</source><volume>3</volume> (<year>2017</year>): <fpage>1107</fpage>&#8211;<lpage>1111</lpage>.<pub-id pub-id-type="pmid">28056116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.5769</pub-id><pub-id pub-id-type="pmcid">PMC5824218</pub-id></mixed-citation></ref><ref id="hed28143-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="hed28143-cit-0046"><string-name name-style="western"><given-names>A. T.</given-names><surname>Nguyen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Luu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Mallen&#8208;St Clair</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early&#8208;Stage Oropharyngeal Squamous Cell Carcinoma</article-title>,&#8221; <source>JAMA Oncology</source><volume>6</volume> (<year>2020</year>): <fpage>1555</fpage>&#8211;<lpage>1562</lpage>.<pub-id pub-id-type="pmid">32816023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.3172</pub-id><pub-id pub-id-type="pmcid">PMC7441465</pub-id></mixed-citation></ref><ref id="hed28143-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="hed28143-cit-0047"><string-name name-style="western"><given-names>P. T.</given-names><surname>Dziegielewski</surname></string-name>, <string-name name-style="western"><given-names>T. N.</given-names><surname>Teknos</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Durmus</surname></string-name>, et&#160;al., &#8220;<article-title>Transoral Robotic Surgery for Oropharyngeal Cancer</article-title>,&#8221; <source>JAMA Otolaryngology. Head &amp; Neck Surgery</source><volume>139</volume> (<year>2013</year>): <fpage>1099</fpage>&#8211;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">23576186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoto.2013.2747</pub-id><pub-id pub-id-type="pmcid">PMC4274181</pub-id></mixed-citation></ref><ref id="hed28143-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="hed28143-cit-0048"><string-name name-style="western"><given-names>Y. M.</given-names><surname>Mowery</surname></string-name> and <string-name name-style="western"><given-names>J. K.</given-names><surname>Salama</surname></string-name>, &#8220;<article-title>Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early&#8208;Stage Oropharyngeal Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume> (<year>2022</year>): <fpage>814</fpage>&#8211;<lpage>817</lpage>.<pub-id pub-id-type="pmid">35077196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.02813</pub-id></mixed-citation></ref><ref id="hed28143-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="hed28143-cit-0049"><string-name name-style="western"><given-names>A. C.</given-names><surname>Nichols</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Theurer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Prisman</surname></string-name>, et&#160;al., &#8220;<article-title>Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long&#8208;Term Results of the ORATOR Trial</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume> (<year>2022</year>): <fpage>866</fpage>&#8211;<lpage>875</lpage>.<pub-id pub-id-type="pmid">34995124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.01961</pub-id></mixed-citation></ref><ref id="hed28143-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="hed28143-cit-0050"><string-name name-style="western"><given-names>A. C.</given-names><surname>Nichols</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Theurer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Prisman</surname></string-name>, et&#160;al., &#8220;<article-title>Radiotherapy Versus Transoral Robotic Surgery and Neck Dissection for Oropharyngeal Squamous Cell Carcinoma (ORATOR): An Open&#8208;Label, Phase 2, Randomised Trial</article-title>,&#8221; <source>Lancet Oncology</source><volume>20</volume> (<year>2019</year>): <fpage>1349</fpage>&#8211;<lpage>1359</lpage>.<pub-id pub-id-type="pmid">31416685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30410-3</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>